CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials-Reference-Cited by-同舟云学术

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Published:2018-03 Issue:3 Volume:29 Page:687-693
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Goss G.,Tsai C.-M.,Shepherd F.A.,Ahn M.-J.,Bazhenova L.,Crinò L.,de Marinis F.,Felip E.,Morabito A.,Hodge R.,Cantarini M.,Johnson M.,Mitsudomi T.,Jänne P.A.,Yang J.C.-H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/687/24530938/mdx820.pdf

Reference30 articles.

1. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer;Peters;Cancer Treat Rev,2016

2. Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer;Baik;J Thorac Oncol,2015

3. NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer, Version 4.2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (14 February 2017, date last accessed).

4. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

5. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting the T790M mutation in non-small cell lung cancer (NSCLC) using brain metastasis MR radiomics: a study with an imbalanced dataset;Discover Oncology;2024-09-14

2. Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics;Frontiers in Neurology;2024-08-30

3. Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors;JAMA Oncology;2024-08-15

4. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control;Scientific Reports;2024-06-25

5. Adjuvant immunotherapy and targeted therapy in early and locally advanced resectable lung cancer: expanding treatment tentacles?;Breathe;2024-06